MedicineBiology

Chimeric Anti-CD20 (IDEC-C2B8) Monoclonal Antibody Sensitizes a B Cell Lymphoma Cell Line to Cell Killing by Cytotoxic Drugs

A. Demidem, Tammy Lam, S. Alas, K. Hariharan, N. Hanna, B. Bonavida

1997.6.1CANCER BIOTHERAPY AND RADIOPHARMACEUTICALS

DOI: 10.1089/cbr.1997.12.177

tlooto Summary

It is demonstrated that C2B8 antibody potentiates the sensitivity of DHL-4 tumor cells to several cytotoxic agents, suggesting that combination treatments with C2B8 antibody and drugs may be of clinical benefit in the treatment of patients.

Abstract

Abstract is not available.

Citation format

DEMIDEM, A., et al. Chimeric anti-cd20 (IDEC-C2B8) monoclonal antibody sensitizes a b cell lymphoma cell line to cell killing by cytotoxic drugs. CANCER BIOTHERAPY AND RADIOPHARMACEUTICALS, 1997, 12: 177–186.